clinical trial · NCT06347133
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
HypertriglyceridemiaPlozasiran InjectionPlacebo
brief summary
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
started
May 21, 2024
primary completion
Jun 1, 2026
completion
Sep 8, 2026
last updated
Sep 25, 2026
official title
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol